Ciplox 750 mg Film-coated Tablets

देश: आयरलैंड

भाषा: अंग्रेज़ी

स्रोत: HPRA (Health Products Regulatory Authority)

इसे खरीदें

सक्रिय संघटक:

CIPROFLOXACIN HYDROCHLORIDE

थमां उपलब्ध:

Accord Healthcare Limited

ए.टी.सी कोड:

J01MA; J01MA02

INN (इंटरनेशनल नाम):

CIPROFLOXACIN HYDROCHLORIDE

डोज़:

750 milligram(s)

फार्मास्यूटिकल फॉर्म:

Film-coated tablet

प्रिस्क्रिप्शन प्रकार:

Product subject to prescription which may not be renewed (A)

चिकित्सीय क्षेत्र:

Fluoroquinolones; ciprofloxacin

प्राधिकरण का दर्जा:

Marketed

प्राधिकरण की तारीख:

2004-07-02

उत्पाद विशेषताएं

                                Health Products Regulatory Authority
18 December 2018
CRN008RG5
Page 1 of 28
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Ciplox 750 mg Film-coated Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 750 mg of ciprofloxacin (as
hydrochloride).
For the full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Film-coated Tablet
White or yellowish, 10 x 19 mm oval, biconvex, film-coated tablets.
Scored on one
side and side-wall scored, marked ‘C750’ on one side.
The tablets can be divided into equal halves.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Ciplox 750 mg film-coated tablets are indicated for the treatment of
the following
infections (see sections 4.4 and 5.1). Special attention should be
paid to available
information on resistance to ciprofloxacin before commencing therapy.
Consideration should be given to official guidance on the appropriate
use of
antibacterial agents.
_Adults_

Lower respiratory tract infections due to Gram-negative bacteria
- exacerbations of chronic obstructive pulmonary disease
- broncho-pulmonary infections in cystic fibrosis or in bronchiectasis
- pneumonia

Chronic suppurative otitis media

Acute exacerbation of chronic sinusitis especially if these are caused
by
Gram-negative bacteria

Urinary tract infections

Gonococcal uretritis and cervicitis

Epididymo-orchitis including cases due to _Neisseria gonorrhoeae_

Pelvic inflammatory disease including cases due to _Neisseria
gonorrhoeae _
Health Products Regulatory Authority
18 December 2018
CRN008RG5
Page 2 of 28
_In the above genital tract infections when thought or known to be due
to _
_Neisseria gonorrhoeae it is particularly important to obtain local
information _
_on the prevalence of resistance to ciprofloxacin and to confirm
susceptibility _
_based on laboratory testing._

Infections of the gastro-intestinal tract (e.g. travellers’
diarrhoea)

Intra-abdominal infections

Infections of the skin and soft tissue caused by Gr
                                
                                पूरा दस्तावेज़ पढ़ें
                                
                            

इस उत्पाद से संबंधित अलर्ट देखें

दस्तावेज़ इतिहास देखें